Maze Therapeutics, Inc.

Maze Therapeutics, Inc. , based in the US, focuses on creating precision medicines for chronic kidney diseases by utilizing advancements in human genetics to develop innovative therapies. Maze Therapeutics, Inc. specializes in precision medicine development aimed at chronic kidney disease.

Founded in 2018 in San Francisco, US, the company was established by Bernhard Klein, Jonathan Widawski, Maria Mesquita, and Thomas M. Currently, Maria Mesquita serves as the CEO. In February 2026, Maze Therapeutics, Inc. raised USD 40 million in venture debt funding from Hercules Capital.

Maze Therapeutics has completed 5 deals to date, with a current company valuation of USD 485. 46 mn. Maze Therapeutics specializes in developing precision medicines that target chronic kidney disease, leveraging significant advancements in human genetics to create innovative therapies. Their primary product pipeline includes treatments aimed at mimicking the effects of rare protective genetic variants to potentially halt or reverse the progression of kidney diseases, with a particular focus on APOL1 kidney disease.

The company utilizes its proprietary Compass platform, which emphasizes variant functionalization, to inform the design of these medicines. Their offerings cater to a range of end users, including patients suffering from chronic kidney diseases and healthcare providers seeking effective treatment options. Maze Therapeutics primarily operates in the North American market, with a vision to expand its therapeutic solutions globally as the clinical trials advance. Maze Therapeutics engages in revenue generation through strategic partnerships and collaborations within the biotechnology sector, focusing on the development and commercialization of their precision medicines.

Revenue streams may include contractual agreements with healthcare organizations or pharmaceutical partners for the joint development of therapies, as well as potential licensing deals for their proprietary technologies. The company’s flagship program targeting APOL1 kidney disease indicates a potential for substantial market demand, particularly from healthcare providers looking for novel treatment options. The financial structure of these transactions typically involves milestone payments associated with clinical trial progress, alongside royalties on future product sales as the therapies move towards market approval. The company will use the February 2026 funding to support ongoing operations and strengthen liquidity after replacing its prior loan facility.